We are live on ! Find out more
ABBV icon

AbbVie

4,138 hedge funds and large institutions have $282B invested in AbbVie in 2026 Q1 according to their latest regulatory filings, with 191 funds opening new positions, 1,749 increasing their positions, 1,727 reducing their positions, and 182 closing their positions.

New
Increased
Maintained
Reduced
Closed

178% more capital inflows, than outflows

Capital inflows: $56.4B | Capital outflows: $20.3B

5% more first-time investments, than exits

New positions opened: 191 | Existing positions closed: 182

1% more repeat investments, than reductions

Existing positions increased: 1,749 | Existing positions reduced: 1,727

1.18% less ownership

Funds ownership: 74.67% → 73.5% (-1.2%)

1% less funds holding

Funds holding: 4,192 → 4,138 (-54)

11% less call options, than puts

Call options by funds: $2.21B | Put options by funds: $2.5B

13% less funds holding in top 10

Funds holding in top 10: 200 → 175 (-25)

Holders
4,138
Holders Change
-54
Holders Change %
-1.29%
% of All Funds
50.19%
Holding in Top 10
175
Holding in Top 10 Change
-25
Holding in Top 10 Change %
-12.5%
% of All Funds
2.12%
New
191
Increased
1,749
Reduced
1,727
Closed
182
Calls
$2.21​B
Puts
$2.5​B
Net Calls
-⁠$286​M
Net Calls Change
-⁠$267​M

ABBV Hedge Fund Activity: Q1 2026 in Review

4,138 of the 8,244 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q1 2026, worth a combined $282B — down 6.3% from $301B a quarter earlier.

Buyers outnumbered sellers: 191 funds opened new ABBV positions and 182 closed out — a net gain of 9 holders — while 1,749 added to existing stakes and 1,727 trimmed.

The largest buyer was Fisher Asset Management, adding an estimated $1.88B. The largest seller was Charles Schwab, cutting an estimated $2.71B.

  • 4,138 institutional investors held AbbVie (ABBV) as of Q1 2026, down from 4,192 in Q4 2025.
  • Funds reported $282B of AbbVie stock for Q1 2026, down 6.3% quarter-over-quarter.
  • 191 funds opened new AbbVie positions in Q1 2026 and 182 closed out, a net change of +9 holders.
  • The largest AbbVie buyer in Q1 2026 was Fisher Asset Management, an estimated $1.88B added.
  • The largest AbbVie seller in Q1 2026 was Charles Schwab, an estimated $2.71B sold.

Based on aggregated 13F filings for Q1 2026.